PRIMARY STUDY

Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial

Key Findings:  The fatty acid amide hydrolase (FAAH) inhibitor ASP3652 was safe and well-tolerated but was not statistically significant in reducing pain symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Micturition and voiding frequency improved in the ASP group over placebo.